TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31266412

Group type: EXPERIMENTAL
Intervention: Intensive Patient Care Program (IPCP)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Control group (usual education, cognitive rehabilitation training, and conventional treatment)
Number of subjects: 242
Study: 28405780

Group type: EXPERIMENTAL
Intervention: Dysmenorrhea Daily Diary (DysDD)
Number of subjects: 355
Study: 25943407

Group type: EXPERIMENTAL
Intervention: Hip extension strength training (n=9)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Hip flexion strength training (n=9)
Number of subjects: 27

Group type: COMPARATOR
Intervention: No intervention (n=9)
Number of subjects: 27
Study: 23952600

Group type: EXPERIMENTAL
Intervention: Tirasemtiv
Number of subjects: 143
Study: 21319378

Group type: EXPERIMENTAL
Intervention: ASA group
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: WASCA group
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: IR+WASCA group
Number of subjects: 96

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 96
Study: 19100304

Group type: EXPERIMENTAL
Intervention: 7-valent conjugated pneumococcal vaccine (PCV7)
Number of subjects: 241

Group type: COMPARATOR
Intervention: 23-valent polysaccharide vaccine (23vPPV)
Number of subjects: 241
Study: 16885405

Group type: EXPERIMENTAL
Intervention: Adiponectin (mean +/- SD 12.8 +/- 8.0 mug/ml)
Number of subjects: 820

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 820
Study: 12527148

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care program (group A)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Regular treatment without pharmaceutical intervention (group B)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 21
Study: 11200128

Group type: EXPERIMENTAL
Intervention: Intrapericardial sclerotherapy with thiotepa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intrapericardial sclerotherapy with tetracyclines
Number of subjects: 0

Group type: COMPARATOR
Intervention: Percutaneous echo‐guided pericardiocentesis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Different agents for sclerosing or cytostatic activity (e.g., bleomycin, thiotepa, radionuclides)
Number of subjects: 0
Study: 8792974

Group type: EXPERIMENTAL
Intervention: Free TRAM flap
Number of subjects: 43

Group type: COMPARATOR
Intervention: Pedicled TRAM flap
Number of subjects: 43
Study: 1739854

Group type: EXPERIMENTAL
Intervention: Memory remediation treatment (compensatory and executive training skills), delivered 6 hours weekly over a 2 1/2‐week period
Number of subjects: 12

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 12
Study: 6338715

Group type: EXPERIMENTAL
Intervention: Mean red cell volume in alcoholic patients
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Mean red cell hemoglobin in alcoholic patients
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Mean red cell volume and mean red cell hemoglobin in patients with excessive alcohol consumption
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Mean red cell volume and mean red cell hemoglobin in patients with decreased alcohol consumption
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Specificity of mean red cell volume
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Specificity of mean red cell hemoglobin
Number of subjects: 625
Study: 30821056

Group type: EXPERIMENTAL
Intervention: Delta power (0.5-4.5 Hz) during non-rapid eye movement sleep
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Sigma power (12-15 Hz) during non-rapid eye movement sleep
Number of subjects: 61
Study: 28558654

Group type: EXPERIMENTAL
Intervention: PPV group (n=84)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (n=84)
Number of subjects: 109
Study: 27652199

Group type: EXPERIMENTAL
Intervention: Minimally invasive SIJ fusion with triangular titanium implants (SIJF, n = 102)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Non-surgical management (NSM, n = 46)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Minimally invasive SIJ fusion with triangular titanium implants (SIJF)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Non-surgical management (NSM)
Number of subjects: 148
Study: 24968990

Group type: EXPERIMENTAL
Intervention: Long-term humidification therapy (LTHT)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 87
Study: 21623930

Group type: EXPERIMENTAL
Intervention: Twice weekly TC regimen
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Tapering TC regimen (3/week for 1st month, 2/week for 2nd month, 1/week for 4th month)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Both regimens (twice weekly and tapering)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Both regimens
Number of subjects: 242
Study: 18953611

Group type: EXPERIMENTAL
Intervention: Preoperative imatinib (600 mg daily for 3, 5, or 7 days)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Postoperative imatinib (for 2 years)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Preoperative imatinib
Number of subjects: 19

Group type: COMPARATOR
Intervention: Imatinib (compared to imatinib-naïve historical control)
Number of subjects: 19
Study: 17351024

Group type: EXPERIMENTAL
Intervention: Reiki
Number of subjects: 16

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 16
Study: 14675236

Group type: EXPERIMENTAL
Intervention: Surgical resection and radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intubation with a plastic prosthesis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stage-directed therapeutic plan
Number of subjects: 0
Study: 12074620

Group type: EXPERIMENTAL
Intervention: Early active mobilization regimen (Group A)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Dynamic splintage regimen (Group B)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study: 11696123

Group type: EXPERIMENTAL
Intervention: midazolam 0.5 mg.kg(‐1)
Number of subjects: 52

Group type: COMPARATOR
Intervention: midazolam vehicle
Number of subjects: 52
Study: 9312763

Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg/night
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 42
Study: 8213511

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 16
Study: 3114964

Group type: EXPERIMENTAL
Intervention: 50 mg Adriamycin once weekly for a period of 6 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: 50 mg Adriamycin once a month over a period of 2 years
Number of subjects: 64
Study: 30672432

Group type: EXPERIMENTAL
Intervention: 75% field capacity irrigation treatment
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 50% field capacity irrigation treatment
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control (100% field capacity)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Water stress (general)
Number of subjects: 3
Study: 27399956

Group type: EXPERIMENTAL
Intervention: 0.05 mL injection volume of abobotulinumtoxinA (10 Speywood units)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.1 mL injection volume of abobotulinumtoxinA (10 Speywood units)
Number of subjects: 0
Study: 25407349

Group type: EXPERIMENTAL
Intervention: Clinical medication reviews (CMRs) facilitated by an expert team (GP and pharmacist)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Usual general practice care
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Clinical medication reviews (CMRs)
Number of subjects: 500
Study: 23266112

Group type: EXPERIMENTAL
Intervention: Quality circles implementation in the experimental group
Number of subjects: 2
Study: 20034973

Group type: EXPERIMENTAL
Intervention: Persistent ST-segment depression (STD) at follow-up ECG
Number of subjects: 3877

Group type: EXPERIMENTAL
Intervention: New ST-segment depression (STD) on follow-up ECG
Number of subjects: 3877

Group type: EXPERIMENTAL
Intervention: Every 1 mm increment of STD on follow-up ECG
Number of subjects: 3877
Study: 18403223

Group type: EXPERIMENTAL
Intervention: Fixed combination of ipratropium and albuterol (IB+ALB)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Albuterol alone (ALB)
Number of subjects: 113
Study: 16687205

Group type: COMPARATOR
Intervention: Darifenacin 7.5mg od (weeks 1-2), 15mg od (week 3)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Oxybutynin ER 10mg od (increasing to 15mg od then 20mg od by week 3)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 12939533

Group type: EXPERIMENTAL
Intervention: 25%O(2)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 30%O(2)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (21% O2)
Number of subjects: 8
Study: 10885682

Group type: EXPERIMENTAL
Intervention: Methylphenidate (10, 25, 20 mg doses)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group (healthy age-matched peers)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: ADHD only
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: ADHD + RD
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 115
Study: 9289443

Group type: EXPERIMENTAL
Intervention: Kliogest hormone therapy
Number of subjects: 17
Study: 1521669

Group type: EXPERIMENTAL
Intervention: 3 mg/kg mexiletine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2 mg/kg mexiletine
Number of subjects: 30

Group type: COMPARATOR
Intervention: saline
Number of subjects: 30
Study: 29218808

Group type: EXPERIMENTAL
Intervention: iPOPP intervention
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Pedometer plus usual care and written information
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care plus written information
Number of subjects: 150
Study: 27475772

Group type: EXPERIMENTAL
Intervention: Social ecologically-based intervention (50-week exercise facilitator intervention with 8 telephone contacts: 3 individual and 5 group)
Number of subjects: 604

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Social ecologically-based intervention
Number of subjects: 604
Study: 24584926

Group type: EXPERIMENTAL
Intervention: Subcutaneous abatacept (ABA) 125 mg/week
Number of subjects: 1134
Study: 22918610

Group type: EXPERIMENTAL
Intervention: Single dose of 0.5 Gy
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Single dose of 1.0 Gy
Number of subjects: 199
Study: 19907348

Group type: EXPERIMENTAL
Intervention: Acupuncture plus usual care
Number of subjects: 175

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 175
Study: 18714228

Group type: EXPERIMENTAL
Intervention: Stable condition with a flat bench
Number of subjects: 20

Group type: COMPARATOR
Intervention: Unstable condition with a Swiss ball
Number of subjects: 20
Study: 16966588

Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 445

Group type: COMPARATOR
Intervention: Coronary Artery Bypass Grafting (CABG)
Number of subjects: 445
Study: 14748460

Group type: EXPERIMENTAL
Intervention: Wet suit
Number of subjects: 12
Study: 10866886

Group type: EXPERIMENTAL
Intervention: 0.07 mg/kg morphine (M1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 0.14 mg/kg morphine (M2)
Number of subjects: 8

Group type: COMPARATOR
Intervention: 0.14 mg/kg oxycodone (O)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 8
Study: 9083824

Group type: EXPERIMENTAL
Intervention: Intensive outpatient treatment (INT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individual therapy (IND)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individual plus group therapy (IND-GRP)
Number of subjects: 0
Study: 8212201

Group type: EXPERIMENTAL
Intervention: Quadruple therapy (prophylactic antilymphoblast globulin - ALG)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Triple therapy (no prophylactic ALG)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Quadruple therapy
Number of subjects: 121

Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 121

Group type: COMPARATOR
Intervention: Immediate CsA group (triple therapy)
Number of subjects: 121
Study: 3544690

Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide 2.5‐5 mg/day
Number of subjects: 106

Group type: COMPARATOR
Intervention: Propranolol 160‐320 mg daily
Number of subjects: 106
Study: 29398422

Group type: EXPERIMENTAL
Intervention: Current users of hormone replacement therapy
Number of subjects: 75587

Group type: COMPARATOR
Intervention: Never-users of hormone replacement therapy
Number of subjects: 75587
Study: 27788847

Group type: EXPERIMENTAL
Intervention: Empirical electrical left atrial appendage isolation along with extensive ablation (group 1)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Extensive ablation alone (group 2)
Number of subjects: 173
Study: 24635827

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938, 5 drops/daily (10^8 colony-forming units), for 4 weeks (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (n=20)
Number of subjects: 40
Study: 22410602

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) intervention, 8 sessions from April 9 to May 28, 2009
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32
Study: 21808448

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 38
Study: 18306334

Group type: EXPERIMENTAL
Intervention: Habitual Activity Estimation Scale (HAES)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Validated 3-day activity diary
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: ActiGraph Accelerometer
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: HAES, diary, and accelerometer
Number of subjects: 14
Study: 16053402

Group type: EXPERIMENTAL
Intervention: Nursing intervention group (n = 38)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Care as usual group (n = 37)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 75
Study: 12450903

Group type: EXPERIMENTAL
Intervention: High-dose vitamin A supplements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10071265

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 192
Study: 7731150

Group type: EXPERIMENTAL
Intervention: Recombinant IFN alpha (subcutaneous injection three times a week for 12 months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Supportive treatment only (Control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Recombinant IFN alpha
Number of subjects: 40
Study: 2046771

Group type: EXPERIMENTAL
Intervention: Hydroquinine (200 mg in the evening and 200 mg before going to bed)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 6790884

Group type: EXPERIMENTAL
Intervention: Cream containing 2% coal tar, 1% diiodohydroxyquinolin, and 0.5% hydrocortisone applied 3 times a day for one month
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo applied on the contralateral region
Number of subjects: 29
Study: 30806520

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Infliximab
Number of subjects: 0
Study: 28103179

Group type: EXPERIMENTAL
Intervention: Intervention message
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 23633748

Group type: EXPERIMENTAL
Intervention: 30 mg mirtazapine nightly for 7 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Baseline (drug-free) nights
Number of subjects: 12
Study: 23964470

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BoNT-A) - 500 units (Dysport) administered via injection
Number of subjects: 384
Study: 19032561

Group type: EXPERIMENTAL
Intervention: Midazolam (1 mg injected i.v. at 30-s intervals until no response to hand grasp test) in Group BS (bilateral spinal anesthesia)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Midazolam (1 mg injected i.v. at 30-s intervals until no response to hand grasp test) in Group US (unilateral spinal anesthesia)
Number of subjects: 42
Study: 17100860

Group type: EXPERIMENTAL
Intervention: Interactive educational programme for peer review groups focusing on treatment of chronic heart failure (CHF)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Interactive educational programme for peer review groups focusing on hypertension treatment in diabetes mellitus type 2 (T2DM)
Number of subjects: 160
Study: 14675803

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU) with social support from a best friend
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU) without social support
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo with social support from a best friend
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo without social support
Number of subjects: 37
Study: 11016449

Group type: EXPERIMENTAL
Intervention: Adapted cow's milk (CM) formula
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrolyzed casein (HC) formula
Number of subjects: 0
Study: 9005381

Group type: EXPERIMENTAL
Intervention: Oral liquid ferrous gluconate (75 mg per diem in 2 vials a day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Solid ferrous gluconate (80 mg per diem in a single effervescent tablet)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Solid ferrous sulphate (105 mg per diem in a single tablet)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ferric protein succinylate (80 mg per diem in 2 vials a day)
Number of subjects: 40
Study: 1282588

Group type: EXPERIMENTAL
Intervention: Ro 42-5892 (0.1 mg/kg) fast infusion
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ro 42-5892 (0.1 mg/kg) slow infusion
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 3839424

Group type: EXPERIMENTAL
Intervention: 12 CMF cycles
Number of subjects: 0

Group type: COMPARATOR
Intervention: No postoperative chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sequential non-cross resistant combinations (CMFP-AV) at full dose
Number of subjects: 0
Study: 30981953

Group type: EXPERIMENTAL
Intervention: Oleo‐calcareous liniment (intervention group)
Number of subjects: 135

Group type: COMPARATOR
Intervention: No liniment (control group)
Number of subjects: 135
Study: 29762731

Group type: EXPERIMENTAL
Intervention: 7.8% of DM SBP (8SBP)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 16.0% of DM SBP (16SBP)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 23.5% of DM SBP (24SBP)
Number of subjects: 41

Group type: COMPARATOR
Intervention: 0% SBP (control)
Number of subjects: 41
Study: 26706237

Group type: EXPERIMENTAL
Intervention: Aflibercept plus FOLFIRI
Number of subjects: 1102

Group type: COMPARATOR
Intervention: Placebo plus FOLFIRI
Number of subjects: 1102

Group type: EXPERIMENTAL
Intervention: Aflibercept plus FOLFIRI (in bevacizumab-pretreated subgroup)
Number of subjects: 1102

Group type: COMPARATOR
Intervention: Placebo plus FOLFIRI (in bevacizumab-pretreated subgroup)
Number of subjects: 1102
Study: 24507910

Group type: EXPERIMENTAL
Intervention: Loss of social influence in young men working with other young men
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gain of social influence in young men working with other young men
Number of subjects: 0

Group type: COMPARATOR
Intervention: Young men working with women
Number of subjects: 0

Group type: COMPARATOR
Intervention: Women working with other women or men
Number of subjects: 0
Study: 22458831

Group type: EXPERIMENTAL
Intervention: Fathers who cut the umbilical cord
Number of subjects: 105

Group type: COMPARATOR
Intervention: Fathers who did not cut the umbilical cord
Number of subjects: 105
Study: 20814323

Group type: EXPERIMENTAL
Intervention: Current exposure to antipsychotic drugs
Number of subjects: 111818

Group type: EXPERIMENTAL
Intervention: Dosage and duration of antipsychotic drug use
Number of subjects: 111818

Group type: EXPERIMENTAL
Intervention: Type of antipsychotic drug
Number of subjects: 111818
Study: 18072822

Group type: EXPERIMENTAL
Intervention: HEP-40 2,400 mg once daily
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: HEP-40 400 mg three times daily
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: HEP-40 800 mg three times daily
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: HEP-40 800 mg twice daily
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 15613421

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (Intrinsa, 150 mug)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (Intrinsa, 300 mug)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (Intrinsa, 150 mug or 300 mug)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 14606376

Group type: EXPERIMENTAL
Intervention: Obese patients with PEEP at 10 cm H2O after recruitment maneuver
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Obese patients with PEEP at 5 cm H2O after recruitment maneuver
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (normal BMI)
Number of subjects: 90
Study: 10721156

Group type: EXPERIMENTAL
Intervention: Felodipin (5 mg q.d.) with further steps including ACE-inhibitors or beta-blockers, increasing Felodipin dose to 100 mg, and adding diuretics if necessary; also 75 mg acetyl-salicylic acid
Number of subjects: 18790

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18790
Study: 7483305

Group type: EXPERIMENTAL
Intervention: Randomized intertrial interval in gap task
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Randomized fixation foreperiod in gap task
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Randomized fixation foreperiod in overlap task
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Randomized gap and overlap trials
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Randomized gap durations
Number of subjects: 5

Group type: COMPARATOR
Intervention: Non-random control sessions
Number of subjects: 5